免疫联合靶向治疗在pMMR/非MSI-H结直肠癌中的研究进展  

Research progress of immune combined targeted therapy in pMMR/non-MSI-H colorectal cancer

作　　者：赖晓静 谢忠 LAI Xiaojing;XIE Zhong(Guangdong Medical University,Zhanjiang 524023,China)

机构地区：[1]广东医科大学,广东湛江524023

出　　处：《临床医学研究与实践》2022年第30期194-198,共5页Clinical Research and Practice

摘　　要：程序性死亡受体-1(PD-1)对错配修复功能缺陷(dMMR)的晚期结直肠癌(CRC)治疗效果显著,但在错配修复功能正常(pMMR)的晚期CRC患者中疗效不佳。然而,临床大多数CRC患者为pMMR/非微卫星高度不稳定性(MSI-H),对免疫检查点抑制剂(ICIs)没有反应。相关研究提示,部分pMMR/非MSI-H CRC患者采用免疫联合靶向治疗的效果显著。本文就pMMR/非MSI-H CRC患者的免疫联合靶向治疗进行综述,以为该类型CRC患者提供新的治疗思路。Programmed cell death receptor-1(PD-1) has a significant therapeutic effect on advanced colorectal cancer(CRC) with deficient mismatch repair(dMMR), but it is not effective in advanced CRC patients with proficient mismatch repair(pMMR). However, most clinical CRC patients were pMMR/non-microsatellite instability-high(MSI-H), and have no response to immune checkpoint inhibitors(ICIs). Relevant studies suggest that some pMMR/non-MSI-H CRC patients have a significant effect in immune combined targeted therapy. This article reviews the immune combined targeted therapy for pMMR/non-MSI-H CRC patients, so as to provide new treatment ideas for this type of CRC patients.

关 键 词：错配修复功能正常 非微卫星高度不稳定性 结直肠癌 免疫治疗 靶向治疗 

分 类 号：R735.3[医药卫生—肿瘤]